Orthopedic practices that spent decades building patient rosters, surgical reputations, and referral networks are now signing over their businesses to private equity-backed management companies – often without their patients ever knowing the ownership changed hands.
Why Orthopedic Groups Are Attractive Targets
Orthopedic surgery sits at a financially favorable intersection: high procedure volume, strong reimbursement rates, and a patient population that skews older and insured. A mid-size regional group handling joint replacements, sports medicine, and spine work can generate millions in annual revenue from a relatively small physician headcount. That profile makes these practices worth acquiring at multiples that smaller primary care groups rarely command.
Private equity firms structure these acquisitions through what the industry calls a “rollup” – buying several regional practices, folding them under a single management entity, standardizing back-office operations, and eventually selling the combined platform to a larger buyer at a higher valuation. The return comes from scale: a group of ten practices is worth far more sold together than ten separate practices sold individually. Orthopedics fits this model well because surgical volume can be tracked, optimized, and presented to future buyers as predictable cash flow.
The physicians selling these practices are not, for the most part, distressed. Many are in their fifties, watching administrative burdens pile up while reimbursement rates stay flat. Managing billing, compliance, staffing, and electronic health records while also operating on patients has become genuinely unsustainable for groups without dedicated management infrastructure. The private equity offer – immediate liquidity plus a continued salary and a stake in the larger platform – arrives at exactly the right psychological moment.
That timing is not accidental. PE-backed consolidators actively scout for practices whose senior partners are within a decade of retirement, whose administrative overhead has grown faster than revenue, or whose hospital system relationship has recently soured. The pitch is tailored to each of those pain points, and it tends to land.
How the Deals Actually Work – and What Changes After
The transaction structure in most orthopedic rollups follows a predictable template. A management services organization, or MSO, acquires the non-clinical assets of the practice: the real estate leases, equipment, billing infrastructure, and brand. The physicians retain nominal ownership of the clinical entity, which is required in most states because corporate practice of medicine laws prohibit non-physicians from owning medical practices outright. In practice, the MSO controls the revenue and the operational decisions while the physicians keep their licenses and their patient relationships.
What changes immediately is the financial reporting rhythm. Practices that previously tracked revenue loosely now feed detailed productivity metrics into centralized dashboards. Physician compensation often shifts from a partnership-style distribution model to a relative value unit – or RVU – based system, meaning doctors are paid more directly for the volume and complexity of procedures they perform. This can benefit high-volume surgeons in the short term, but it also creates pressure that was absent in the old partnership model.
Staffing decisions migrate upward. The new management entity may consolidate billing teams across multiple acquired practices, renegotiate supplier contracts for surgical implants, and standardize which procedures get scheduled at which facilities. These are real efficiency gains, and the MSO operators point to them honestly. But they also mean that decisions once made by the senior partners over lunch are now made by regional operations managers who may never have set foot in the clinic.
Patient experience changes are often subtle at first – longer hold times on the phone, different intake paperwork, new portal software. They become less subtle when a practice is relocated, when a well-regarded physician assistant leaves and is not replaced quickly, or when out-of-network billing errors surface that the old front-desk staff would have caught. None of these outcomes are inevitable, but they are common enough in rollup integrations that patients in markets where consolidation is accelerating should pay attention to billing statements and insurance coverage confirmations more carefully than before.
The same pattern is appearing across healthcare specialties. Regional oral surgery practices selling to DSO networks have followed a nearly identical acquisition logic – PE-backed management entities buying clinical practices, retaining the physicians under employment-style contracts, and building toward a platform sale. The orthopedic wave is larger in dollar terms, but the structure is recognizable.
The Regulatory Blind Spot
Federal antitrust enforcement has historically focused on hospital mergers and large insurer consolidations. Physician group rollups, particularly in specialties outside primary care, have received far less scrutiny – partly because individual transactions are often small enough to fall below mandatory reporting thresholds. A PE firm acquiring a six-physician orthopedic group in a mid-sized metro does not trigger a Hart-Scott-Rodino filing. Acquire twelve such groups across a region over three years, however, and the combined entity controls a meaningful share of orthopedic surgical capacity in markets where patients have few alternatives.
State medical boards regulate licensure and clinical standards but have no jurisdiction over business ownership structures. That gap is where most of the leverage in these transactions lives. The physicians keep their licenses; the PE firm keeps the revenue. Whether that arrangement ultimately harms patient access or drives up facility fees in concentrated markets is a question that regulators are only beginning to ask – and one that physicians who sold five years ago are quietly starting to answer for themselves.
The more immediate tension is for physicians still weighing whether to sell. The liquidity event is real. The operational relief is real. But so is the loss of autonomy over hiring, scheduling, and the pace of clinical work. Several orthopedic surgeons who completed PE-backed transactions have subsequently bought back their practices or departed the platform entirely when the post-acquisition environment diverged from what the letter of intent described. The non-compete clauses attached to these deals – often spanning two to five years and covering broad geographic radii – make that exit expensive.
